lilly glp 1 oral In the same week that Pfizer decided to discontinue the development of danuglipron, an oral, small-molecule GLP-1 receptor agonist aimed at chronic weight management ➡️ report a successful Phase 3 trial Lilly's New Oral GLP-1 Orforglipron

The aptly named Shotsy was founded by Aja Beckett, whose own GLP-1 weight loss journey inspired her to create tools for others on these medications

The TriNetX platform has been used in retrospective cohort studies [25,26,27,28,29,30,31,32,33,34,35,36,37,38] including evaluating risk and health outcomes of patients with substance use disorders including CUD [25, 32, 35] and the associations of GLP-1RAs with cancer [37] and semaglutide with suicidal ideations [38]

El estudio no demuestra, por tanto, que el medicamento sea el causante de los efectos enumerados

The percentage of participants who discontinued the medication due to AE ranged between 20 and 29%